Immediate Impact

1 by Nobel laureates 2 from Science/Nature 59 standout
Sub-graph 1 of 19

Citing Papers

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
2023 Standout
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2023 Standout
2 intermediate papers

Works of Robin K. Dore being referenced

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial
2008
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
2004

Author Peers

Author Last Decade Papers Cites
Robin K. Dore 503 650 707 617 31 1.5k
Michael D. Fallon 464 509 617 639 57 2.0k
Deborah Wenkert 595 456 640 585 45 1.9k
S Bord 322 630 461 1068 30 2.0k
Linda R. Halstead 216 522 496 827 38 2.1k
D. Wattie 330 1098 1083 576 37 2.1k
Christian Rosenquist 314 489 427 410 17 1.5k
Osvaldo Daniel Messina 405 375 498 333 51 1.2k
Giuseppe Girasole 206 638 580 792 21 1.7k
Laura Masi 236 483 751 717 59 1.8k
Ulrike I. Mödder 139 574 727 922 24 1.8k

All Works

Loading papers...

Rankless by CCL
2026